Skip to main content
. 2025 May 20;25:900. doi: 10.1186/s12885-025-14313-7

Fig. 2.

Fig. 2

In 21 patients with advanced LUAD harboring EGFR ex20ins mutations treated with 240 mg/d furmonertinib, the median PFS was 6.15 months (A), the median TTF was 10.78 months (B), and the median OS was 21.67 months (C) as of the follow-up date from January 1, 2021, to March 1, 2024